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Objective To explore the usefulness of incidence–prevalence–mortality (IPM) models in improving estimates of disease epidemiology.
Methods Two artificial and four empirical data sets (for breast, prostate, colorectal, and stomach cancer) were employed in IPM
models.
Findings The internally consistent artificial data sets could be reproduced virtually identically by the models. Our estimates often
differed considerably from the empirical data sets, especially for breast and prostate cancer and for older ages. Only for stomach cancer
did the estimates approximate to the data, except at older ages.
Conclusion There is evidence that the discrepancies between model estimates and observations are caused both by data inaccuracies
and past trends in incidence or mortality. Because IPM models cannot distinguish these effects, their use in improving disease estimates
becomes complicated. Expert opinion is indispensable in assessing whether the use of these models improves data quality or,
inappropriately, removes the effect of trends.
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Introduction
Quantitative descriptions of disease epidemiology, such as
incidence, prevalence and mortality, by age and sex, are
essential inputs for burden of disease studies and cost-
effectiveness analyses of interventions. Such studies serve as an
important source of information for policy-making, planning,
and research prioritization in health care. Empirical observa-
tion is obviously the gold standard for obtaining epidemiolo-
gical information, but empirical data are often incomplete or of
dubious validity. In addition, the validity of estimates tends to
vary even for an individual disease. For example, in instances
where incidence is more difficult to observe than mortality,
more incident cases than deaths are likely to be missed. In this
case, therefore, data on incidence are less complete than those
on mortality, making these two parameters internally incon-
sistent.
One way to circumvent these data limitations is to exploit
the causal structure of the disease process: incidence has to
precede prevalence, and cause-specific mortality can only follow
being diseased. Incorporating the causal structure into a
mathematical model makes it possible to calculate data that
are missing from the observational set and to check for the
internal consistency of observations. An example of the first of
these procedures is the back-calculation of (unobserved) human
immunodeficiency virus (HIV) infection from data on the
incidence of acquired immunodeficiency syndrome (AIDS) (1).
The Global Burden of Disease 1990 study, and many
subsequent national burden of disease studies, made extensive
use of DisMod, a generic mathematical disease model, which
was specially designed to supplement observational data and
check for internal consistency (2). Previously we have
employed a conceptually similar disease model to calculate
unobserved incidence data (3). The present article explores the
usefulness of such generic disease models that describe the
relation between incidence, prevalence and mortality (IPM
models) for improving estimates of disease epidemiology. We
consider whether these models calculate the correct results
and, if so, how useful these results are. Our approach is to apply
two IPMmodels (DisMod and our ownmodel) to two artificial
data sets known to be complete and consistent and to four
high-quality empirical data sets for cancers, drawn fromDutch
registries. The ability of the IPMmodels to describe adequately
the data sets serves as an indicator of their usefulness.
Methods
Artificial data sets
In order to demonstrate that the models can calculate the
correct results, we first used them with internally consistent
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data (formal validity). Data sets for breast and colorectal cancer
were generated by MISCAN, a microsimulation model for the
evaluation of screening programmes (4, 5). MISCAN creates a
cohort of hypothetical individuals, each of whom has a risk of
developing cancer, and, once the disease is present, a survival
drawn from a lognormal distribution. Incidence, prevalence
and mortality data generated by this model are, by definition,
complete and internally consistent.
Empirical data
We applied the IPMmodels to national incidence andmortality
data for breast cancer (ICD-9 code 174), prostate cancer (ICD-
9, code 185), colorectal cancer (ICD-9 codes 153 and 154) and
stomach cancer (ICD-9 code 151). Data averaged for 1991–95,
specified by sex and 5-year age group (up to595 years), were
used. Statistics Netherlands (CBS) collects mortality data by
cause-of-death on a continuous basis using information from
death certificates. Incidence data are collected continuously by
the Dutch Cancer Registry (NKR), which receives its
information from nine regional cancer centres. These data
are based on pathology reports, complemented by national
hospital admission data; death certificates are not used as an
additional source.
The cancer registries do not estimate prevalence data on
a regular basis. The Regional Cancer Centre South (IKZ)
determined the prevalence of the specific cancers for which
incidence has been determined for the eastern part of the
coverage area on 1 January 1993: for all incident cases
registered in the region from 1970 until 1992 the population
registry was checked to determine whether the persons
concerned were still alive. For the same region we obtained
the regional mortality and incidence rates from IKZ, averaged
for 1991–95. Mortality data for this region originated from the
CBS database (region: COROP 36 and 37). Regional data were
specified by sex and 5-year age group (up to585 years).
IPM models
Both DisMod and our model are based on the conceptual
disease model depicted in Fig. 1. The population is described
as being in different states, while transition hazards determine
how people move from one state to another. Within a
population, individuals can be either susceptibles or cases.
Cases may die from their disease, while both cases and
susceptibles are at risk of dying from other causes. There are
consequently three transition hazards: incidence, case-fatality,
and all other mortality. DisMod also includes remission as a
fourth transition hazard, but for our analysis we set this
hazard to zero since cure is not taken into account in the
registered cancer prevalence. The framework in Fig. 1 shows
that the number of cases can be calculated by following an
initially disease-free cohort over time and applying the
transition hazards. Under the important assumption made
in the IPM models that there are no trends in the transition
hazards, time is equal to a patient’s age. The models thus
permit calculation of prevalence at a certain age from the
prevalence at the previous age and the mortality and incidence
in the age interval.
Although they are based on this common conceptual
model, the actual model calculations differ. DisMod uses a set
of linear differential equations that describe the transitions
between the states. The solution of the equations is
approximated by using the finite differences method.
Incidence and case-fatality hazards are required as input
parameters, and we approximated them using rates. Case-
fatality rates were calculated from mortality data and the
prevalence calculated from our own model (see below and
Annex). Since DisMod cannot calculate data for age groups
over 90 years and can only handle a limited number of age
groups, we specified 5-year age groups from 15 years to
89 years. The calculation is performed using a competing risk
life table (6). General mortality data for the Netherlands for
1991–95 reported by CBS were specified.
Our model gives an exact solution based on an
analytical solution of a continuous time Markov process (7).
We refer to it here as the analytical model. Using a
spreadsheet we implemented the formula for the calculation
of prevalence from incidence and mortality probabilities (see
Annex). Mortality and incidence rates per 5-year age group
up to595 years served as input. We first interpolated these
data to 1-year age groups up to 595 years and then
converted them to probabilities (see Annex for formulas and
methods). Apart from the different calculation method
(approximate versus exact), the analytical model thus also
differs from DisMod in the way it treats mortality. Mortality
probability relates to the total population, whereas case-
fatality, used in DisMod, concerns only prevalent cases. In
the event of inconsistent data, the mortality probability may
exceed the predicted prevalence, resulting in negative
prevalence estimates in the analytical model, which is not
possible if case-fatality is used.
623Bulletin of the World Health Organization 2002, 80 (8)
Use of models to estimate disease epidemiology
The models were assessed by comparing the calculated
prevalence with the observed data. We extrapolated the
observed prevalence data from 585 years to 595 years by
applying the cubic-spline methodology and using life-table
derived mean ages of 89.6 years and 90.8 years, for men and
women aged585 years, respectively.
Results
Application of the internally consistent MISCAN data to the
models resulted in prevalence estimates that were virtually
identical to those generated by MISCAN and to one another.
When the observed data were applied the results of the two
models were also practically identical. The reproducibility of
MISCAN data and the consistency of the results from the two
models suggest that they calculated the correct results.
The prevalences calculated from national data by the
analytical model are shown with the observed prevalences in
Figs. 2–5. The model estimates increase with age, at first
exponentially, but subsequently at a slower pace. At ages
>80 years the estimates reach a maximum and then decline.
The decline at older ages is most apparent for stomach cancer,
the calculated prevalence decreasing to zero or even to negative
values; the smallest decline is that for breast cancer.
The predicted prevalences are nearly always larger than
the observed ones. However, stomach cancer is exceptional in
this respect in that the estimate approximates to the observed
value, except for ages >85 years. For prostate and breast cancer
the discrepancy is large (depending on age, the model
calculations are up to about two and three times larger,
respectively), while for colorectal cancer it is intermediate (up
to about 1.5 times larger).
Discussion
The results from the artificial data sets support the validity of
the IPM models: despite the difference of a lognormally
distributed survival in MISCAN and a piecewise exponentially
distributed survival in the IPM models, the latter are able to
reproduce the MISCAN prevalence very well. In addition the
two IPM models produce virtually the same results, a further
indication of validity. Nevertheless, when registered incidence
andmortality data were used, the predicted prevalence differed
considerably from that observed, and for stomach cancer
impossible results were produced. Three possible reasons for
these discrepancies are considered below.
Regional differences
The regionally observed prevalence data, to which the national
estimates are compared, may not be representative of the
national situation. Breast cancer screening was introduced in
the IKZ region between 1993 and 1997, whereas in the rest of
theNetherlands it was introduced around 1990. Cause-specific
prostate cancer mortality is unequally distributed (8). We
explored the influence of regional differences by applying
regional incidence and mortality data to the model. A
comparison of the results of these calculations (not shown)
with the empirical data revealed that the differences between
estimates and observations were similar, and, if anything,
somewhat larger than the discrepancies we found on using
national data in the models. The regional variation in disease
epidemiology therefore could not explain the differences.
Past trends
Because both models are based on the assumption that
incidence and mortality are in a steady state, the occurrence of
trends in incidence or mortality would lead to discrepancies
between the model estimates and the observations. Prevalence
is a stock variable, comprising all past incident cases that are still
alive. It is therefore dependent on incidence and case-fatality
from the past as well as the present.
Cancer incidence has a tendency to rise for the tumours
we studied, because of increased awareness and screening, and
for other, unknown, reasons (9, 10). The incidence of breast
cancer, for example, is presumed to show a secular trend of 1%
per year (11), on top of which an additional increase is imposed
because of the introduction of breast cancer screening around
1990 in the Netherlands. A notable exception to this rising
incidence is presented by stomach cancer, for which there has
been a long-term secular decline (9, 10).
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Cancermortality, meanwhile, remains relatively stable (9,
10, 12–14), except for stomach cancer and female colorectal
cancer, for which it has declined.With increasing incidence and
constant mortality, prevalence increases over time but does so
less rapidly than incidence, since it also includes persons who
became incident in the past. Consequently, applying current
incidence and mortality to the model produces estimates that
are higher than the observations. The largest deviations were
seen concordantly for breast cancer and prostate cancer, the
two cancers for which the rise in incidence has been most
apparent, mainly because of screening.
In an additional analysis old incidence data for breast
cancer were used in themodel in order to checkwhether trends
could explain the discrepancies. The risk ofmortality for breast
cancer patients remains elevated for more than 20 years after
diagnosis. We therefore used regional incidence data for 1968–
72 (12), obtaining an estimated prevalence close to the
observed value for 1993. This shows that the trend in incidence
may indeed cause a difference. Nevertheless it cannot explain
the discrepancy entirely: the average incidence that cases
prevalent on 1 January 1993 were exposed to lies somewhere
between the 1991–95 and the 1968–72 incidences. Although
we believe the effect of the trends in incidence is considerable,
other factors evidently also play a role.
Data inaccuracies
Inaccuracies in the epidemiological estimates are the third
possible reason for the differences between observations and
model predictions. Statistics on mortality by cause-of-death in
theNetherlands are assumed to be reliable, although no studies
are known in which the completeness of the death registry has
been investigated in absolute terms. Compared with other
European countries, in the Netherlands the detection fraction
for cancer as a cause of death is high (15). Furthermore, it has
been argued that deaths from cancer in general are not likely to
be missed (16), although misclassification between cancers
may occur for older age groups. Thus it is unlikely that
underregistration of cancer deaths is a causative factor in our
generally higher prevalence estimates, especially with regard to
young and middle-aged people. Nevertheless, the under-
estimation of mortality remains a possible explanation for
discrepancies. Since we did not include excess mortality from
other diseases in our model we implicitly assumed it to be zero.
However, cancer patients also suffer from an increased risk of
dying from diseases other than cancer (17). We believe that, in
addition to the effect of trends, the impact of ignoring this
factor makes an important contribution to the discrepancies.
At older ages, where multiple medical problems are
frequent and pathological examinations are performed
relatively infrequently, misclassification of cancer deaths may
lead to the overregistration of deaths for the more frequent
types of cancer. This would cause prevalence estimates to be
too low and could contribute to the decline of our prevalence
estimates at older ages.
Cancer incidence data in the Netherlands are reliable.
Nevertheless, because they are based on pathology and
hospitalization data, those incident cancer cases that did not
undergo a pathological examination and were not hospitalized
would be systematically excluded from registration. It has been
estimated that this would lead to an underregistration of 1.3–
1.6% (18, 19). Moreover, some cases that are included in
pathology or hospitalization registries are missed. This non-
systematic exclusion has been estimated to occur in 2.2% of
cases (19). A completeness of approximately 96.2% is thus
achieved, which is comparable to the level of completeness in
several other national cancer registries (19). This incompleteness
seems to be concentrated in the highest age groups; one study
suggested that missed incident cases mostly related to elderly
persons with cancer of the digestive tract (18), although this was
not confirmed in another study (19). The underregistration of
incidencemay help to explain the impossible negative prevalence
calculated for stomach cancer and the decline in the estimates for
colorectal cancer at older ages (Fig. 4 and Fig. 5).
Underregistration cannot, however, explain the finding
that the prevalence estimates are generally higher than the
observations for the other age groups. Multiple malignancies
can contribute to this. The incidence registry counts the
number ofmalignancies, whereas the prevalence data are based
on the number of persons with a malignancy. Consequently, a
personwithmultiplemalignancies in the same organ is counted
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more than once in the incidence data but only once in the
prevalence data. For breast and colorectal cancer suchmultiple
malignancies may be present, and can account for up to 10%
and 15%, respectively, of the incident cases (J.-W. Coebergh,
personal communication, 2000). This would make our
prevalence estimate too high and would explain part of the
differences, but not more than the 10% or 15% by which the
incidence is overestimated.
The incompleteness of prevalence data could also be a
factor contributing to the higher estimates. Although based on
regional incidence data, prevalence data may be somewhat less
complete because cancer registration was less complete in its
early years than more recently (19). Since only old cases are
underestimated in this way, prevalence is only affected if the
survival time is long. Furthermore, this underestimation might
be diminished by the opposite phenomenon: overestimation of
prevalence resulting from incomplete ascertainment of
survival status. The latter incompleteness would be very small,
however, since deaths are unlikely to be missed, although
problems may arise when persons have moved out of the
country. We believe that the underestimation of prevalence
data is not large and that it is unlikely to explain a large part of
the differences.
Conclusion
The test with the artificial data supports the formal validity of
IPM models. However, the confrontation with the four
empirical data sets of presumed high quality shows that, in
practice, there may be large discrepancies between measure-
ments and calculations. The discrepancies are likely to be
attributable in considerable measure to past trends in incidence
but also to data inaccuracies, the most important source of
which seems to be underestimation of mortality as a result of
ignoring excess mortality from other causes.
The model cannot distinguish between the effects of
trends and the effects of data inaccuracies. Separating these
effects would require a dynamic model that describes the
disease processes over time, and could incorporate the effects
of past trends. Unfortunately, such a model would be much
more complex. Moreover, since the trends would have to be
quantified, more input data would be required, and these have
proved difficult to obtain. Consequently, a dynamic analysis is
often not feasible.
In practice use of IPM models such as DisMod occurs
particularly when data are incomplete and/or of low quality. In
such circumstances it is impossible to distinguish between the
apparent inconsistencies that represent real data problems and
those that are attributable to past trends. This complicates the
use of such models in improving estimates of disease
epidemiology. Considerable judgement has to be exercised
when the disadvantage of forcing data to comply with the
assumption of a steady state is weighed against the goal of
reducing the unreliability of the data. Expert knowledge on
disease epidemiology and registries remains indispensable for
guiding this process. n
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Re´sume´
L’utilisation de mode`les dans les estimations en matie`re d’e´pide´miologie
Objectif Etudier l’utilite´ des mode`les d’incidence, de pre´valence
et de mortalite´ pour ame´liorer les estimations en matie`re
d’e´pide´miologie.
Me´thodes On a applique´ les mode`les d’incidence, de pre´valence
et de mortalite´ a` deux se´ries de donne´es artificielles et quatre se´ries
de donne´es empiriques (pour les cancers du sein, de la prostate, de
l’estomac et du cancer colo-rectal).
Re´sultats Les se´ries de donne´es artificielles ayant une cohe´rence
interne ont pu eˆtre reproduites virtuellement de manie`re identique
par les mode`les. Souvent, nos estimations diffe´raient sensible-
ment des donne´es empiriques, particulie`rement pour les cancers
du sein et de la prostate et pour les personnes les plus aˆge´es. Pour
le cancer de l’estomac seulement, les estimations se rappro-
chaient des donne´es, sauf lorsqu’il s’agissait des personnes les
plus aˆge´es.
Conclusion Il semble que les e´carts entre les estimations fournies
par les mode`les et les observations soient cause´s a` la fois par
l’inexactitude des donne´es et par les tendances passe´es en matie`re
d’incidence ou de mortalite´. Les mode`les d’incidence, de
pre´valence et de mortalite´ ne permettant pas de distinguer entre
les effets tenant a` l’inexactitude des donne´es et ceux dus aux
tendances passe´es, il devient difficile de les utiliser pour ame´liorer
les estimations. L’avis de spe´cialistes est donc indispensable pour
e´valuer si l’utilisation de ces mode`les ame´liore la qualite´ des
donne´es ou si, malencontreusement, elle fait disparaıˆtre l’influence
des tendances.
Resumen
Uso de modelos para estimar la epidemiologı´a de enfermedades
Objetivo Determinar la utilidad de los modelos basados en la
incidencia, la prevalencia y la mortalidad para mejorar las
estimaciones epidemiolo´gicas.
Me´todos Los modelos de incidencia, prevalencia y mortalidad
(IPM) se aplicaron a dos conjuntos de datos artificiales y cuatro
empı´ricos (para el ca´ncer de mama, pro´stata, colon y recto, y
esto´mago).
Resultados Los modelos consiguieron reproducir de forma casi
ide´ntica los conjuntos de datos artificiales, internamente cohe-
rentes. En cambio, nuestras estimaciones difirieron a menudo
considerablemente de los conjuntos de datos empı´ricos, sobre todo
en el caso de los ca´nceres de mama y de pro´stata y en lo que
respecta a las personas de ma´s edad. So´lo en el caso del ca´ncer de
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esto´mago las estimaciones se aproximaron a los datos,
exceptuando de nuevo las personas mayores.
Conclusio´n Hay indicios de que las discrepancias entre las
estimaciones arrojadas por los modelos y las observaciones se
deben tanto a inexactitudes de los datos como a las tendencias
seguidas por la incidencia y la mortalidad en el pasado. Dado
que los modelos IPM no permiten distinguir esos efectos,
resulta complicado usarlos para mejorar las estimaciones. La
opinio´n de los expertos se revela por tanto como indispensable
para evaluar si el uso de esos modelos mejora la calidad de los
datos o elimina de manera indebida el efecto de las
tendencias.
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Annex
The analytical model
For the disease process described in Fig. 1, the prevalence
proportion at exact age n can be calculated from the prevalence
at the previous age and mortality and incidence probability.
With respect to Fig. 1, pn=Cn/(Cn+ Sn) is the prevalence
at exact age n, and mn = (Fn+1 – Fn)/(Cn + Sn) is the mortality
probability of age group n, where S = susceptibles, C = cases
and F= cause-specific deaths. Because of competing risks, the
incidence probability of susceptibles at age n (in) does not have
a straightforward expression in terms of the model compart-
ments depicted in Fig. 1. Given pn, mn and in, we can calculate
prevalence at age n + 1 using the following expression (7):
pn+l = [pn – mn + in *(l – pn)]/(l – mn) eq.{1}
For this expression to be valid, a steady state situation
and independence of all other causes of death must be
assumed. Furthermore, the hazards are assumed to be constant
within a given age interval. In order to minimize deviations
from this assumption, we used 1-year age intervals. Therefore,
we first interpolated the rates specified per 5-year interval to
1-year age groups, using the cubic-spline method.
The interpolated rates were then converted into the
appropriate input formats, using the following expressions:
IRsn+l = IRpn+l/(l – pn)
in= l – exp(– IRsn) eq.{2}
mn = l – exp(– MRn), if pn>0, otherwise 0,
where IRsn is the incidence rate among susceptibles, IRpn is the
incidence rate in the population, andMRn is the cause-specific
mortality rate in the population, all for the age group n (the
other parameters are mentioned above).
Calculation of the incidence among susceptibles from
population data requires information on prevalence. Since
prevalence itself has to be calculated in the model, we used the
results from the previous age to calculate incidence among
susceptibles. This produced a small deviation.
From these 1-year data the prevalence at exact age n was
calculated using eq.{1}. We transformed the outcome of the
model to amean prevalence for age n by averaging the results of
two successive ages. This can be given in either 1-year or 5-
year age groups.
The DisMod model
The DisMod model can be downloaded from the Internet (at
URL: http://www.hsph.harvard.edu/organizations/bdu/dis-
mod/index.html). (Two versions of DisMod are available at
this URL – we used DisMod I in our analyses.) For this model
the same assumptions of steady state, constant hazards in the
age interval and independence of other-cause mortality are
required.
We approximated input hazards by rates. The appro-
priate input formats were calculated using the following
expressions:
CFRn=LN[l – {(mn – rn *(l – pn))/pn}], ifmn<pn, otherwise 0 eq.{3}
rn= [IRn *(l – exp(–CFRn–1)) –CFRn–1 *(l – exp(– IRn))]/[IRn–CFRn–1],
whereCFRn is the case-fatality rate for age group n and rn is the
probability of making two transitions in age group n (the other
parameters are mentioned above).
Conversions to the appropriate input formats weremade
by using the interpolated data (1-year age intervals). We used
the prevalence calculated by the previous model to compute
case-fatality. Because the formula for calculating rn requires the
CFRn as input data, and vice versa, we used the case-fatality
rate of the previous age (CFRn-1) in this calculation. This
produced a slight deviation.
We then back-transformed the input data to 5-year age
groups. DisMod was then used to calculate annual incidence
and mortality rates and mean prevalence per 5-year age
group.
Research
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